|Bid||36.27 x 400|
|Ask||36.74 x 900|
|Day's Range||36.03 - 36.42|
|52 Week Range||29.83 - 36.60|
|PE Ratio (TTM)||26.64|
|Earnings Date||Oct 31, 2017|
|Dividend & Yield||1.28 (3.53%)|
|1y Target Est||38.30|
The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair .
"How Moats Translate into Sustainable Competitive Advantages" is a five-part moat investing education series that explores the primary sources of economic moats.
Conatus Pharmaceuticals (CNAT) announced the appointment of Keith W. Marshall as executive vice president, chief operating officer and chief financial officer.
General Motors stock has a rare combination of a breakdown valuation and zippy price momentum. That is, it trades at eight times forward earnings estimates, making it less than half as expensive as the ...
The London-listed consumer group is doing what activist Nelson Peltz wants Procter & Gamble to do—but M&A may be an ulterior motive.
Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.
Shares of Aerie Pharmaceuticals, Inc. (AERI) have moved up 15.8% in the last week on positive news for its lead drug, Rhopressa.
"Prescription drug prices are out of control. The drug prices have gone through the roof," Trump says at a Cabinet meeting.
Pfizer Inc. today announced full results from the Phase 2 clinical trial of the investigational, next-generation tyrosine kinase inhibitor lorlatinib that exhibited clinically meaningful activity against lung tumors and brain metastases in a range of patients with ALK-positive and ROS1-positive advanced non-small cell lung cancer , including those who were heavily pretreated.
Customers may be starting to shop for over-the-counter drugs in the same way they shop for groceries—with a keener eye for cost and content—and this could be painful for consumer-health companies.
So far in October, of the 22 analysts covering Eli Lilly (LLY), four have suggested a “strong buy,” while ten analysts have suggested a “buy.”
Pharmaceutical third-quarter earnings are nearly upon us, and Guggenheim's Tony Butler and Allen Cha provide their thoughts on the upcoming results. Butler and Cha write that the hurricanes are a factor ...